Hyperreflective Foci In Oct Image As A Biomarker Of Poor Prognosis In Diabetic Macular Edema Treating With Conbercept

Purpose: To investigate the change of hyperreflective foci(HF)in diabetic macular edema(DME)patients during the treatment of intravitreal Conbercept(IVC)injections.Methods: We retrospectively investigated 17 patients(30 eyes)with DME who had received IVC injections from 2016 to 2018.The best corrected visual acuity(BCVA),central macular thickness(CMT)as well as the locations and numbers of HF at each visit were analyzed.Results: After 3 times of IVC injections,BCVA(LogMAR)improved from 0.70(0.40-1.24)to 0.40(0.28-0.70)(p<0.0001),CMT decreased from545.0μm(440.25μm-788.50μm)to 384.5μm(258.5μm-548.3μm)(p<0.0001).The baseline numbers of HF in inner retinal layers,outer retinal layers and subretinal space were 4.00(3.00-7.00),4.00(1.00-7.50)and 0.00(0.00-1.25)respectively.After the IVC treatment,HF numbers in all retinal layers decreased significantly.The numbers of HF in inner retinal layer at baseline was positively associated with final BCVA(LogMAR)and CMT.The decrease of HF in each retinal layer as well as the decrease oftotal HF in all retinal layers were related to the reduction of CMT.Conclusion: Conbercept is effective and safe in the treatment of DME.HF could be a predictive factor for the final visual acuity of DME patients treating with Conbercept.